KR100312473B1 - 항종양성 인돌로피롤로카르바졸 유도체 - Google Patents

항종양성 인돌로피롤로카르바졸 유도체 Download PDF

Info

Publication number
KR100312473B1
KR100312473B1 KR1019960706296A KR19960706296A KR100312473B1 KR 100312473 B1 KR100312473 B1 KR 100312473B1 KR 1019960706296 A KR1019960706296 A KR 1019960706296A KR 19960706296 A KR19960706296 A KR 19960706296A KR 100312473 B1 KR100312473 B1 KR 100312473B1
Authority
KR
South Korea
Prior art keywords
formula
compound represented
compound
group
meaning described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019960706296A
Other languages
English (en)
Korean (ko)
Other versions
KR970702869A (ko
Inventor
가쓰히사 고지리
히사오 곤도
미쓰루 오오꾸보
히로유끼 스다
히로하루 아라까와
Original Assignee
나가사까 겐지로
반유 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나가사까 겐지로, 반유 세이야꾸 가부시끼가이샤 filed Critical 나가사까 겐지로
Priority claimed from PCT/JP1995/000868 external-priority patent/WO1995030682A1/ja
Publication of KR970702869A publication Critical patent/KR970702869A/ko
Application granted granted Critical
Publication of KR100312473B1 publication Critical patent/KR100312473B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1019960706296A 1994-05-09 1995-05-02 항종양성 인돌로피롤로카르바졸 유도체 Expired - Fee Related KR100312473B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11948394 1994-05-09
JP94-119483 1994-05-09
JP14564894 1994-06-03
JP94-145648 1994-06-03
PCT/JP1995/000868 WO1995030682A1 (en) 1994-05-09 1995-05-02 Antitumor indolopyprolocarbazole derivative

Publications (2)

Publication Number Publication Date
KR970702869A KR970702869A (ko) 1997-06-10
KR100312473B1 true KR100312473B1 (ko) 2002-06-24

Family

ID=26457215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960706296A Expired - Fee Related KR100312473B1 (ko) 1994-05-09 1995-05-02 항종양성 인돌로피롤로카르바졸 유도체

Country Status (14)

Country Link
EP (2) EP0760375B1 (enExample)
JP (1) JP3038921B2 (enExample)
KR (1) KR100312473B1 (enExample)
CN (2) CN1285605C (enExample)
AT (2) ATE283863T1 (enExample)
AU (1) AU683749B2 (enExample)
CA (1) CA2190007C (enExample)
CL (1) CL2004001117A1 (enExample)
DE (2) DE69533833T2 (enExample)
DK (2) DK1264836T3 (enExample)
ES (2) ES2230433T3 (enExample)
HK (1) HK1000890A1 (enExample)
PT (2) PT760375E (enExample)
TW (1) TW313566B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050058444A (ko) * 2002-08-23 2005-06-16 반유 세이야꾸 가부시끼가이샤 인돌로피롤로카르바졸 유도체의 제조법
CN101585861B (zh) * 2009-07-03 2012-10-24 复旦大学 N-糖基萘并咔唑化合物及其合成方法和应用
WO2025082431A1 (zh) * 2023-10-18 2025-04-24 正大天晴药业集团股份有限公司 一种吲哚衍生物治疗头颈部肿瘤的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011145A1 (en) * 1991-11-29 1993-06-10 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94274A0 (en) * 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
EP0528030B1 (en) * 1990-05-11 1997-09-17 Banyu Pharmaceutical Co., Ltd. Antitumor be-13793c derivative
JP3603322B2 (ja) * 1992-12-14 2004-12-22 萬有製薬株式会社 インドロピロロカルバゾール誘導体の製造法
JP3707075B2 (ja) * 1994-06-13 2005-10-19 萬有製薬株式会社 グリコシルトランスフェラーゼをコードする遺伝子及びその用途
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011145A1 (en) * 1991-11-29 1993-06-10 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives

Also Published As

Publication number Publication date
ES2206501T3 (es) 2004-05-16
CL2004001117A1 (es) 2005-04-22
AU683749B2 (en) 1997-11-20
DK0760375T3 (da) 2003-12-29
DE69532198T2 (de) 2004-08-26
JP3038921B2 (ja) 2000-05-08
ATE255121T1 (de) 2003-12-15
DE69533833T2 (de) 2005-12-15
KR970702869A (ko) 1997-06-10
EP0760375A4 (en) 2002-03-27
HK1000890A1 (en) 2004-01-09
PT760375E (pt) 2004-04-30
EP1264836B1 (en) 2004-12-01
CN1106400C (zh) 2003-04-23
CN1285605C (zh) 2006-11-22
TW313566B (enExample) 1997-08-21
PT1264836E (pt) 2005-02-28
DE69532198D1 (de) 2004-01-08
EP1264836A1 (en) 2002-12-11
DE69533833D1 (de) 2005-01-05
CN1153518A (zh) 1997-07-02
DK1264836T3 (da) 2005-03-07
CN1513865A (zh) 2004-07-21
CA2190007A1 (en) 1995-11-16
EP0760375B1 (en) 2003-11-26
CA2190007C (en) 2003-04-15
ES2230433T3 (es) 2005-05-01
AU2353595A (en) 1995-11-29
HK1067948A1 (en) 2005-04-22
EP0760375A1 (en) 1997-03-05
ATE283863T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
HU211556A9 (en) Pyrroloindole derivatives related to dc-88a compound
EP0269025B1 (en) Rebeccamycin analogs
JP3469580B2 (ja) 新規なペプチド誘導体
EP0323171B1 (en) Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them
KR100347218B1 (ko) N-옥시카보닐치환된5'-데옥시-5-플루오로사이티딘
KR19980703203A (ko) 신규 펩티드 유도체
US5922860A (en) Antitumor indolopyrrolocarbazole derivatives
KR100293578B1 (ko) 인돌로피롤로카르바졸유도체의제조방법
Castro-Pichel et al. A facile synthesis of ascamycin and related analogues
US5804564A (en) Antitumor indolopyrrolocarbazole derivatives
WO1995030682A1 (en) Antitumor indolopyprolocarbazole derivative
JPH05247055A (ja) スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
WO1991018003A1 (fr) Derive antitumoral de be-13793c
DK170892B1 (da) 14-Oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetra-deca-2,4,6-trien-forbindelser, fremgangsmåde til fremstilling heraf, farmaceutiske præparater der indeholder forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler og en kultur af mikroorganismen Streptomyces sandaensis
JP4047383B2 (ja) 抗ウイルス活性を有するセスキテルペン誘導体
JP3038921B2 (ja) 抗腫瘍性インドロピロロカルバゾール誘導体
JPWO1995030682A1 (ja) 抗腫瘍性インドロピロロカルバゾール誘導体
JP4038245B2 (ja) 新規なフェナンスリジニウム誘導体
JPWO1997011947A1 (ja) 抗ウイルス活性を有するセスキテルペン誘導体
WO1997009339A1 (fr) Derives antitumoraux d'indolopyrrolocarbazole
HU210499B (en) Process for preparing 6-o-alkylelsamicin a deriv.s and pharmaceutical compn.s contg. them
HK1000890B (en) Antitumor indolopyrolocarbazole derivative
US4861774A (en) Method of treating tumors using tetracyclo compounds
KR820001589B1 (ko) 데메틸 메이탄시노이드 화합물의 제조방법
CA2413037C (en) Intermediates for producing antitumor indolopyrrolocarbazole derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20090401

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091011

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091011

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000